AU3435293A - Method for determining cytolytic T cell precursors - Google Patents
Method for determining cytolytic T cell precursorsInfo
- Publication number
- AU3435293A AU3435293A AU34352/93A AU3435293A AU3435293A AU 3435293 A AU3435293 A AU 3435293A AU 34352/93 A AU34352/93 A AU 34352/93A AU 3435293 A AU3435293 A AU 3435293A AU 3435293 A AU3435293 A AU 3435293A
- Authority
- AU
- Australia
- Prior art keywords
- cells
- tumor
- antigen
- pbmcs
- cytolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 28
- 239000002243 precursor Substances 0.000 title claims description 18
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims description 14
- 210000004027 cell Anatomy 0.000 claims description 73
- 210000004881 tumor cell Anatomy 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 230000009089 cytolysis Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229940123591 Natural killer cell inhibitor Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 description 21
- 230000002101 lytic effect Effects 0.000 description 17
- 230000000259 anti-tumor effect Effects 0.000 description 14
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 11
- 239000012636 effector Substances 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 6
- 230000006037 cell lysis Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Substances OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584314 Homo sapiens Myc target protein 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100030625 Myc target protein 1 Human genes 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82393392A | 1992-01-21 | 1992-01-21 | |
| US823933 | 1992-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3435293A true AU3435293A (en) | 1993-08-03 |
Family
ID=25240169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU34352/93A Abandoned AU3435293A (en) | 1992-01-21 | 1993-01-07 | Method for determining cytolytic T cell precursors |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0624189A4 (no) |
| JP (1) | JPH07503134A (no) |
| KR (1) | KR950700402A (no) |
| AU (1) | AU3435293A (no) |
| CA (1) | CA2128424A1 (no) |
| FI (1) | FI943422A0 (no) |
| NO (1) | NO942660L (no) |
| WO (1) | WO1993014189A1 (no) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU664560B2 (en) * | 1991-05-23 | 1995-11-23 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6280962B1 (en) | 1991-11-25 | 2001-08-28 | Yoreh Biotechnologies Ltd. | Whole blood/mitogen assay for the early detection of a subject with cancer and kit |
| US6322989B1 (en) | 1991-11-25 | 2001-11-27 | Yoreh Biotechnologies, Ltd. | Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit |
| US6352826B1 (en) | 1991-11-25 | 2002-03-05 | Yoreh Biotechnologies, Ltd. | Method and kit for the detection of retroviral specific antibodies in seronegative individuals |
| US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| WO1995029193A2 (en) | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
| US5843648A (en) * | 1995-01-10 | 1998-12-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods |
| US6951917B1 (en) | 1995-09-26 | 2005-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | MHC-class II restricted melanoma antigens and their use in therapeutic methods |
| US7501501B2 (en) | 1995-09-26 | 2009-03-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
| ATE244300T1 (de) * | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US20040156861A1 (en) | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
| CA2272924A1 (en) * | 1996-11-22 | 1998-05-28 | Shiloov Medical Technologies Ltd. | A whole blood/mitogen assay for the early detection of a subject with cancer and kit |
-
1993
- 1993-01-07 CA CA002128424A patent/CA2128424A1/en not_active Abandoned
- 1993-01-07 JP JP5512545A patent/JPH07503134A/ja active Pending
- 1993-01-07 AU AU34352/93A patent/AU3435293A/en not_active Abandoned
- 1993-01-07 EP EP93902961A patent/EP0624189A4/en not_active Withdrawn
- 1993-01-07 WO PCT/US1993/000083 patent/WO1993014189A1/en not_active Application Discontinuation
- 1993-01-07 KR KR1019940702508A patent/KR950700402A/ko not_active Application Discontinuation
-
1994
- 1994-07-15 NO NO942660A patent/NO942660L/no unknown
- 1994-07-19 FI FI943422A patent/FI943422A0/fi not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU664560B2 (en) * | 1991-05-23 | 1995-11-23 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07503134A (ja) | 1995-04-06 |
| WO1993014189A1 (en) | 1993-07-22 |
| EP0624189A1 (en) | 1994-11-17 |
| EP0624189A4 (en) | 1995-05-17 |
| CA2128424A1 (en) | 1993-07-22 |
| FI943422A (fi) | 1994-07-19 |
| NO942660L (no) | 1994-09-16 |
| KR950700402A (ko) | 1995-01-16 |
| FI943422A0 (fi) | 1994-07-19 |
| NO942660D0 (no) | 1994-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Coulie et al. | Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells | |
| Balch et al. | Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients | |
| Patarroyo et al. | Association of a B-cell alloantigen with susceptibility to rheumatic fever | |
| Mathew et al. | The anergic state in sarcoidosis is associated with diminished dendritic cell function | |
| Dean et al. | The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens | |
| Tiemessen et al. | Lack of suppressive CD4+ CD25+ FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma | |
| Fukuchi et al. | Increased frequency of 6-thioguanine-resistant peripheral blood lymphocytes in Werner syndrome patients | |
| Hou et al. | Establishment of the reference intervals of lymphocyte function in healthy adults based on IFN-γ secretion assay upon phorbol-12-myristate-13-acetate/ionomycin stimulation | |
| WO1994020120A1 (en) | In vitro assay measuring degree of activation of immune cells | |
| Brod et al. | Lymphokine regulation of CD45R expression on human T cell clones. | |
| AU3435293A (en) | Method for determining cytolytic T cell precursors | |
| CN108697734A (zh) | 表现出适应性表型的nk细胞以及制备和使用方法 | |
| Chen et al. | Elevation of interleukin-10 levels in malignant pleural effusion | |
| Mori et al. | Transcriptional response to ionizing radiation in lymphocyte subsets | |
| US7413869B2 (en) | Method for determining potency of antigenic presenting cell based vaccines | |
| Weynants et al. | Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival | |
| Zhang et al. | EZH2 identifies the precursors of human natural killer cells with trained immunity | |
| Wattrang et al. | Phenotypic characterization of Eimeria tenella-specific chicken T-cells responding to in vitro parasite antigen re-stimulation | |
| Marino et al. | Differential IL-7 responses in developing human thymocytes | |
| Thompson et al. | Measurement of daughter cell accumulation during lymphocyte proliferation in vivo | |
| Ma et al. | Follicular cytotoxic CD8 T cells present high cytokine expression, and are more susceptible to Breg-mediated suppression in non-small cell lung cancer | |
| Roberts et al. | Proliferative and cytotoxic responses of human peripheral blood lymphocytes to autologous malignant effusions: An analysis at the clonal level | |
| Ebert | Do the CD45RO+ CD8+ intestinal intraepithelial T lymphocytes have the characteristics of memory cells? | |
| Kasakura | MLC stimulatory capacity and production of blastogenic factor in patients with chronic lymphatic leukemia and Hodgkin's disease | |
| Ko et al. | Diagnostic methods to assess the numbers, phenotype, and function of primary and engineered NK cells: Methods to predict prognosis and treatment outcome |